Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers

NCT06255197 | Recruiting DMC

• 1 other identifier: LungReal_01
• Study Type: observational
• Target: 60,000
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a multi-center, observational, real-world study for patients with resected lung cancers in China. With the help of a properly designed data processing algorithm and extensively performed data quality assurance, this study aims to harness the potential of real-world big data to (1) describe characteristics and treatment patterns and their evolving trends; (2) discover features associated with overall survival; and (3) address recently-emerging clinical questions.

Conditions

Lung Cancer; Lung Adenocarcinoma; Lung Squamous Cell Carcinoma; Non Small Cell Lung Cancer; Small-cell Lung Cancer

Keywords

Lung cancer; Surgery; Real world

Outcome Measures

Primary Outcomes (1)

• Overall survival

  Time from surgery to death from any cause.

  January 2014 to December 2031

Secondary Outcomes (4)

• Baseline characteristics of included participants

  January 2014 to December 2028

• Treatment patterns of included participants

  January 2014 to December 2028

• Pathological characteristics of included participants

  January 2014 to December 2028

• Features associated with overall survival

  First analysis is anticipated to be performed from April to August 2024; the final analysis is anticipated in 2032.

Study Arms (1)

Patients with surgically resected lung cancer

Patients who were diagnosed with lung cancer and received surgical resection in participating medical centers during the designed study period.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Participants eligible for this study would be screened from consecutive patients who received surgical resection for lung malignancies in participating medical centers during the designed study period.

You may qualify if:

• Age above 18.
• Have received surgical resection for lung malignancies.

You may not qualify if:

• Participants whose data are of low quality, poor completeness or poor internal linkage.

Sponsors & Collaborators

• Cancer Institute and Hospital, Chinese Academy of Medical Sciences: lead

Study Sites (1)

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, 100021, China

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Carcinoma, Bronchogenic; Bronchial Neoplasms

Study Officials

• Jie He, MD-PhD

  National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS and PUMC

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Fengwei Tan, MD-PhD

CONTACT

+8601087787792; tanfengwei@126.com

Renda Li, MD

CONTACT

lirenda@cicams.ac.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 4, 2024
• First Posted: February 13, 2024
• Study Start: November 4, 2019
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2031
• Last Updated: February 16, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)